Aethlon Medical
AEMD
10 hedge funds and large institutions have $1.69M invested in Aethlon Medical in 2018 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, reducing their positions, and closing their positions.
25% more funds holding
Funds holding: 8 → 10 (+2)
12% more capital invested
Capital invested by funds: $1.51M → $1.69M (+$181K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$78.4K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$78.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$20K |
| 2 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$19K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$13K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$3K |
| 5 |
PMFA
Plante Moran Financial Advisors
Southfield,
Michigan
|
-$1K |
AEMD Hedge Fund Activity: Q2 2018 in Review
10 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Aethlon Medical (AEMD) for Q2 2018, worth a combined $1.69M — up 12% from $1.51M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new AEMD positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $78.4K. The largest seller was Bank of New York Mellon, cutting an estimated $20K.
- 10 institutional investors held Aethlon Medical (AEMD) as of Q2 2018, up from 8 in Q1 2018.
- Funds reported $1.69M of Aethlon Medical stock for Q2 2018, up 12% quarter-over-quarter.
- 2 funds opened new Aethlon Medical positions in Q2 2018 and 0 closed out, a net change of +2 holders.
- The largest Aethlon Medical buyer in Q2 2018 was Geode Capital Management, an estimated $78.4K added.
- The largest Aethlon Medical seller in Q2 2018 was Bank of New York Mellon, an estimated $20K sold.
Based on aggregated 13F filings for Q2 2018.